Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

2023239 citationsJournal Articlegold Open Access

Authors

Travere Therapeutics.

Good health and well-being

Published in: The Lancet

Volume 402, Issue 10417, pp. 2077-2090

Field-Weighted Citation Impact: 47.13